40 results
In Person in Paris and online EuroPCR 2022 celebrates the best of both worlds
09 May 2022
EuroPCR is celebrating being back home in Paris, in-person, for the first time in 3 years. This year’s international Course will see both a complete on-site programme and a full digital experience, bringing the community together to share and learn.

EuroPCR 2021 - Unprecedented global outreach and online interactivity during an innovative livestreamed edition
25 May 2021
Paris, France. 21 May 2021. Since 1989, EuroPCR has constantly pioneered innovative educational tools and formats to help the interventional cardiovascular community effectively share their knowledge, skills and practice. Rising up to the challenge of the pandemic, the 31st annual edition was fundamentally rethought, reshaped and...

A new meta-analysis supports elective revascularization and medical therapy for reducing cardiac death
18 May 2021
The ISCHEMIA trial found no significant difference between an invasive vs. a conservative strategy in patients with chronic coronary syndromes and moderate to severe ischemia at a mean of 3.2 years. However, the cumulative difference in the estimates of cardiac death between the invasive and conservative...

One-year results from the FUTURE-II trial
18 May 2021
A decade already passed from the first use of bioresorbable vascular scaffold in percutaneous coronary interventions. The first studies - by using surrogate endpoints - showed some superiority of BRS vs. metallic drug-eluting stent in terms of the so-called vascular restoration therapy with recovery of vasomotion...

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :

EBC MAIN trial results – what is new and what will change in left main stenting?
18 May 2021
The European Bifurcation Club Left Main (EBC MAIN) trial addressed the issue of provisional single stent versus upfront double stenting in 467 patients with true bifurcation distal left main disease.
So far, only one other randomized trial, DKCRUSH-V (n=482), has addressed the same research question, showing better...

Cool AMI EU pivotal trial- final results after trial discontinuation following ad interim analysis
18 May 2021
Results of the interim analyses performed after 12 months in the first 111 patients enrolled in phase II Cool AMI trial evaluating safety and effectiveness of systemic therapeutic hypothermia as an adjunctive therapy in anterior STEMI undergoing PCI as compared to PCI only. Analyses showed significant...

2021 Ethica Award: Dr. Marie-Claude Morice to receive the 2021 Andreas Grüntzig Ethica Award
17 May 2021
Paris, France, 10 May 2021 - EuroPCR, taking place online from 18 to 20 May 2021, will be an opportunity for the interventional cardiovascular community to come together and benefit from interactive training with their peers. At this year’s web-based event, Dr. Marie-Claude Morice will be presented with the Andreas...

We CARE: a joint initiative by PCR and Stent – Save a Life!
07 May 2021
Paris, France. Since the start of the COVID-19 pandemic, patients have been consistently deprived of timely cardiovascular treatment. This is due in part to measures taken in response to the sanitary crisis, but it is also due to patients' own unwillingness to seek medical help, even...
